CONTINUATION PAGE: STAY WITHIN MARGINS INDICATED 
Principal Investigator/Program Director {Last, first, middle): 
Synder D, Findley D, Forman S, Nademanee A, O’Donnell M, Krance R. Fractionated total body 
irradiation and high dose cyclophosphamide: a preparative regimen for bone marrow transplantation for 
patient with hematologic malignancies in first complete remission. Blut 57:7, 1988. 
Falletta J, Cushing B, Lauer S, Bell B, Mahoney D, Castleberry R, Krance R. Phase I evaluation of 
diaziquone in childhood cancer. A Pediatric Group Study. Invest New Drugs 8:167, 1990. 
Newman E, Vilacorte D, Testi A, Krance R, Harris M, Ravindranath Y, Pinkel D. Biochemical 
interactions between methotrexate and 1-^-D-arabinosuranosylcytosine in children with acute lymphocytic 
leukemia. Cancer Chemother Pharmacol 27:60, 1990. 
Krance R, Newman E, Ravindranath Y, Harris M, Brecher M, Wimmer R, Land V, Pullen J, Crist W, 
Pinkel D. "Spread-out" or "up-front" intermediate dose methotrexate and ara-C in continuation therapy 
for childhood non-T, non-B acute lymphoblastic leukemia. A pilot study. Cancer 67:550, 1991. 
Crist W, Shuster J, Look T, Borowitz M, Behm F, Bowman P, Frankel L, Pullen J, Krance R, Steuber 
P, Cammitta B, Amylon M, Link M, Land V. Current results of studies of immunophenotype-, age- and 
leukocyte- based therapy for children with acute lymphoblastic leukemia. Leukemia 6:162-167, 1992. 
Hurwitz CA, Krance R, Schell MJ, Santana VM, Brenner MK, Ribeiro R, Roberts WM, Mahmoud H, 
Belt J, Crom W, Shearer PD, Mirro J Jr. Current strategies for treatment of acute myeloid leukemia at 
St. Jude Children’s Research Hospital. Leukemia 6:39-43, 1992. 
Krance RA, Raimondi SC, Dubowy R, Estrada J, Borowitz M, Behm F, Land VJ, Pullen J, Carroll AJ. 
The t(12;17)(pl3;q21) in early pre-B acute lymphoid leukemia. Leukemia 6:251-255, 1992. 
Rill DR, Moen RC, Buschle M, Bartholomew C, Foreman NK, Mirro J Jr, Krance RJ, Ihle JD, Brenner 
MK. Retrovirus mediated gene transfer for analysis of relapse and marrow reconstitution following 
autologous marrow transplantation. Blood 79:2694-2700, 1992. 
Krance R, Heslop H, Mahmoud H, Ribeiro R, Douglass E, Hurwitz C, Santana V, Kun L, Horowitz MM, 
Brenner M. Anti-pan T-lymphocyte ricin A chian immunotoxin (H65-RTA) and methylprednisolone for 
acute graft-versus-host disease prophylaxis following allogeneic bone marrow transplantation from HLA- 
identical sibling donors. Bone Marrow Transplant 11:33-36, 1992. 
Brenner MK, Rill DR, Moen RC, Krance RA, Mirro J Jr, Anderson WF, Ihle JN. Gene marking to trace 
origin of relapse after autologous bone marrow transplantation. Lancet 341:85-86, 1993. 
Mahmoud HH, Rivera GK, Hancock ML, Krance RA, Kun LE, Behm FG, Ribeiro RC, Sandlund JT, 
Crist WM, Pui C-H. Clinical significance of low leukocyte count with blasts in cerebrospinal fluid of 
newly diagnosed children with acute lymphoblastic leukemia. N Eng J Med 329:314-319, 1993. 
Heideman RL, Douglass EC, Krance RA, Fontanesi J, Langston JA, Sanford RA, Kovnar EH, Ochs J, 
Kuttesch J, Jenkins JJ, Fairclough DL, Kun LE. High dose chemotherapy and autologous bone marrow 
rescue followed by interstitial and external beam radiotherapy in newly diagnosed pediatric malignant 
gliomas. J Clin Oncol 11:1458, 1993. 
Hurwitz CA, Head D, Raimondi S, Krance R, Mirro J Jr, Ayers GD, Behm FG. Distinctive 
immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. Blood (in press). 
Brenner, MK, Rill DR, Holladay MS, Heslop HE, Moen RC, Buschle M, Krance RA, Anderson WF , Ihle 
JN. Does autologous marrow infusion restore long-term hemopoiesis in cancer patients? Lanret 
Recombinant DNA Research, Volume 19 
[515] 
